Vertex (VRTX) Follow Up

As suspected, VRTX is down over 5% today - similar to the December decline when the high drop out rate (9% at the time) was disclosed. The drop out rate went to 11% and given the atmosphere that the FDA approval process is under these days, VRTX has a lot of work to do to assuage those drop out worries and so more time and tests will be needed. I really soured on how the analyst community covers these biotech plays after the Dendreon (DNDN) experience. Had I listened to them, I would have let a near six-figure gain go by selling my long position in DNDN on their advice. Granted, there are a whole group of different analysts covering VRTX, but the recent overwhelming positive analyst coverage on VRTX has led many astray, at least in the short term.